Clinical Trial Update: Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating daytime versus nighttime dosing of mirabegron for female patients with overactive bladder syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder Syndrome

Drugs mentioned

• Mirabegron (mirabegron)

Snippet

Sponsor: Far Eastern Memorial Hospital | Conditions: Overactive Bladder Syndrome | Phase 4 | Status: UNKNOWN